avelumab

Open Access
Clinical Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma With Prior Avelumab Versus Pembrolizumab Therapy
AKINORI MINATO, NOBUKI FURUBAYASHI, TOSHIHISA TOMODA, HIROYUKI MASAOKA, YOOHYUN SONG, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, KENTARO KUROIWA, NARIHITO SEKI, IKKO TOMISAKI, MOTONOBU NAKAMURA, KENICHI HARADA and NAOHIRO FUJIMOTO

Anticancer Research August 2024, 44 (8) 3419-3426; DOI: https://doi.org/10.21873/anticanres.17162
You have access
Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy
TETSUYA SHINDO, KOHEI HASHIMOTO, ATSUSHI TAKAHASHI, SHINTARO MIYAMOTO, YASUHARU KUNISHIMA, SHUNSUKE SATO, FUMIMASA FUKUTA, YOSHIKI HIYAMA, AKIO TAKAYANAGI, RYUICHI KATO, ATSUSHI WANIFUCHI, YOHEI UEKI, MANABU OKADA, HIDEKI ADACHI, KO KOBAYASHI, TOSHIAKI TANAKA and NAOYA MASUMORI; on behalf of the Sapporo Medical University Urologic Oncology Consortium

Anticancer Research March 2024, 44 (3) 1271-1279; DOI: https://doi.org/10.21873/anticanres.16922
You have access
Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study
NOBUKI FURUBAYASHI, AKINORI MINATO, TOSHIHISA TOMODA, YOSHIFUMI HORI, KEIJIRO KIYOSHIMA, TAKAHITO NEGISHI, YUSUKE HARAGUCHI, TOSHIKI KOGA, KENTARO KUROIWA, NAOHIRO FUJIMOTO and MOTONOBU NAKAMURA

Anticancer Research December 2023, 43 (12) 5689-5698; DOI: https://doi.org/10.21873/anticanres.16774

Main menu

User menu

Search

avelumab